

NDA 212304

**NDA APPROVAL**

Corium, Inc.  
Attention: Terry Ocheltree, PhD, RPh  
Head of Regulatory Affairs and Quality Assurance  
4558 50<sup>th</sup> Street Southeast  
Grand Rapids, MI 49512

Dear Dr. Ocheltree:

Please refer to your New Drug Application (NDA) dated September 29, 2019, received September 30, 2019, and your amendments, submitted pursuant to Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Adlarity (donepezil transdermal system).

We acknowledge receipt of your amendment dated September 11, 2021, which constituted a complete response to our July 23, 2020, action letter.

This NDA provides for the use of Adlarity (donepezil transdermal system) for the treatment of mild, moderate, and severe dementia of the Alzheimer's type.

### **APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Patient Package Insert, and Instructions for Use) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the Guidance for Industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

The SPL will be accessible via publicly available labeling repositories.

### **CARTON AND CONTAINER LABELING**

Submit final printed carton and container labeling that are identical to the carton and container labeling submitted on March 10, 2022, and the transdermal system overlay backing side labels submitted on January 19, 2022, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the Guidance for Industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 212304.**” Approval of this submission by FDA is not required before the labeling is used.

### **DATING PERIOD**

Based on the stability data submitted to date, the expiry dating period for Adlarity (donepezil transdermal system) shall be 24 months from the date of manufacture when stored at 5°C ± 3°C .

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric studies requirement for this application because necessary studies are impossible or highly impracticable, as Alzheimer’s disease only occurs in the adult population.

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-*

*Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs.*<sup>3</sup>

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.<sup>4</sup> Information and Instructions for completing the form can be found at FDA.gov.<sup>5</sup>

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Justine Kankam, Regulatory Project Manager, at 1-(301)-837-7650 or via email at [NanaYaa.Kankam@fda.hhs.gov](mailto:NanaYaa.Kankam@fda.hhs.gov).

Sincerely,

*{See appended electronic signature page}*

Teresa Buracchio, MD  
Director  
Division of Neurology 1  
Office of Neuroscience  
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling

- Prescribing Information
- Patient Package Insert
- Instructions for Use

---

<sup>3</sup> For the most recent version of a guidance, check the FDA guidance web page at

<https://www.fda.gov/media/128163/download>.

<sup>4</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

<sup>5</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

TERESA J BURACCHIO  
03/11/2022 12:34:28 PM